BBIO BridgeBio Pharma
- 25.200
- -0.280-1.10%
- 25.250
- +0.050+0.20%
BridgeBio Pharma News
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Leerink Partners Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $44
Positive Outlook on BridgeBio Pharma's BBP-812 Gene Therapy: Buy Rating Reaffirmed
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BridgeBio Pharma Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $46
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $43
BridgeBio Pharma Analyst Ratings
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Receives 'Buy' Rating Amid Positive Regulatory Outlook for Acoramidis
Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
Optimistic Patent Litigation Outlook Strengthens Buy Rating for BridgeBio Pharma
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
BridgeBio Pharma Analyst Ratings
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
Analysis
Price Target
No Data
No Data